Key Takeaways
- MUVON Therapeutics, a clinical-stage biotechnology company, has appointed Christine Günther, MD, PhD, as Chief Technology Officer (CTO) effective December 1, 2025.
- Dr. Günther brings over 30 years of experience in translating regenerative medicine innovations from development to clinical application, with expertise in iPSC technology, cell and gene therapy development, and clinical translation.
- MUVON Therapeutics is focused on developing a novel platform for the regeneration of skeletal muscle tissue, with an initial focus on the treatment of stress urinary incontinence in women.
- The company’s personalized tissue-engineered treatment has shown promising results in a Phase 2 clinical trial, with an 87% responder rate and a favorable safety and tolerability profile.
- Dr. Günther’s appointment is expected to propel the company through the next stage of its journey, with her expertise and leadership instrumental in advancing MUVON’s technology platform to patients in need.
Introduction to MUVON Therapeutics and Dr. Christine Günther
MUVON Therapeutics, a clinical-stage biotechnology company, has announced the appointment of Dr. Christine Günther as its new Chief Technology Officer (CTO), effective December 1, 2025. Dr. Günther is a renowned cell therapy pioneer with over 30 years of experience in translating regenerative medicine innovations from development to clinical application. She brings a unique blend of medical innovation and technology leadership, with a proven track record as a biotech entrepreneur, scaling sustainable cell therapy businesses from startup to exit. Her expertise spans iPSC (stem cell) technology, cell and gene therapy development, CMC, GMP manufacturing, regulatory affairs, and clinical translation, making her an ideal leader to advance MUVON’s technology platform.
Dr. Günther’s Background and Experience
Dr. Günther has built an exceptional track record over 30+ years in cell therapy, including over 12 years as CEO and Medical Director of Munich-based biotech apceth (now Minaris Regenerative Medicine). She grew the company into one of Europe’s leading contract development and manufacturing organizations (CDMO) in cell and gene therapy before its acquisition by Hitachi Chemical in 2019. Previously, she served as Medical Director at the Bavarian Stem Cell and Cord Blood Bank, where she led GMP-compliant stem cell programs and helped establish a major public cord blood bank. From 2021 to 2025, she served as Entrepreneur-in-Residence at Evotec, advancing key initiatives to develop the company’s cell therapy strategy with a particular focus on the iPSC-based platform. She subsequently became Managing Director of the GMP Cell Factory in Italy, leading its transition to clinical-stage readiness.
MUVON Therapeutics’ Mission and Focus
MUVON Therapeutics is dedicated to the discovery and development of personalized regenerative treatments, with the goal of establishing them as an affordable standard of care. The company’s initial focus is on the treatment of stress urinary incontinence in women, a condition that affects over 150 million women worldwide. MUVON’s mission is to help patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle tissue. Founded in 2020 as a clinical-stage life science spin-off from the University of Zurich, MUVON Therapeutics was accelerated by the Wyss Zurich Translational Center from 2021-2025.
Phase 2 Clinical Trial Results
MUVON Therapeutics’ personalized tissue-engineered treatment has shown promising results in a Phase 2 clinical trial, with an 87% responder rate and a favorable safety and tolerability profile. The study, known as SUISSE-MPC2, evaluated the company’s investigational, tissue-engineered autologous muscle precursor cell (MPC)-based therapy (MPCCOL) in women with stress urinary incontinence who had failed prior conservative treatments. The primary endpoint was the change from baseline to 6 months in stress incontinence episode frequency (IEF), with 24-hour pad weight as the key secondary endpoint. The study met both endpoints with high statistical significance (p<0.0001), demonstrating the potential of MUVON’s treatment to address serious unmet medical needs.
Conclusion and Future Prospects
The appointment of Dr. Christine Günther as CTO is expected to propel MUVON Therapeutics through the next stage of its journey, with her expertise and leadership instrumental in advancing the company’s technology platform to patients in need. With her proven track record in cell therapy and regenerative medicine, Dr. Günther is well-positioned to help MUVON Therapeutics achieve its mission of establishing personalized regenerative treatments as an affordable standard of care. As the company continues to develop its novel platform for the regeneration of skeletal muscle tissue, it is likely to make significant progress in addressing serious unmet medical needs and improving the lives of patients worldwide.
